Research Papers:
The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
Metrics: PDF 1912 views | HTML 2046 views | ?
Abstract
Guangzhi Ma1,2,*, Jing Zhang3,*, Liyuan Yin1,*, Hai Jiang4, Weiwei Zhang5, Yanlin Song1 and Ming Liu1
1Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu 610041, P. R. China
2Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China
3Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China
4Department of Orthopedic Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China
5Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, P. R. China
*These authors have contributed equally to this work
Correspondence to:
Ming Liu, email: [email protected]
Keywords: pretreatment T790M, NSCLC, EGFR TKI, prognosis, meta-analysis
Received: November 17, 2016 Accepted: February 20, 2017 Published: March 15, 2017
ABSTRACT
Purpose: The outcome of pretreatment epidermal growth factor receptor (EGFR) T790M mutation in EGFR mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) is controversial, this study aimed to evaluate the prognostic role of pretreatment T790M in advanced NSCLC patients treated with EGFR TKIs.
Results: A total of 7 eligible studies containing 179 cases and 281 controls were included in the meta-analysis. The pooled hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) were 2.21 (95% CI 1.49-3.29, P<0.001) and 1.24 (95% CI 0.90-1.71, P=0.186), respectively. We also did subgroup analyses on OS and PFS according to patients from various districts.
Methods: Identified literatures from various databases were reviewed. A meta-analysis was performed to evaluate the prognostic role of pretreatment EGFR T790M in advanced EGFR mutant patients treated with EGFR TKIs.
Conclusions: Pretreatment T790M may be a poor prognostic factor for PFS in advanced NSCLC patients treated with EGFR TKIs. However, no significant prognostic effect was found between pretreatment T790M mutation and OS. More studies are needed to demonstrate the prognostic role of pretreatment T790M mutation in advanced NSCLC patients.

PII: 16222